Bioptik Technology Cash Flow Conversion Efficiency
Bioptik Technology cash flow conversion efficiency. Based on the latest financial reports, Bioptik Technology (4161) has a cash flow conversion efficiency ratio of 0.055x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$53.21 Million ≈ $1.68 Million USD) by net assets (NT$974.69 Million ≈ $30.71 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Bioptik Technology (2017–2025)
Cash flow conversion efficiency of Bioptik Technology from 2017 to 2025. This chart illustrates how Bioptik Technology's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Bioptik Technology stock price for real-time trading data and today's change.
Bioptik Technology Cash Flow Conversion Ratio Explained
Bioptik Technology cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Bioptik Technology Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bioptik Technology ranked by their cash flow conversion efficiency. Also see 4161 market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Korea Electronic Certification Authority Inc
KQ:041460
|
0.036x |
|
Cypress Technology Co Ltd
TWO:3541
|
0.021x |
|
Retail Food Group Ltd
AU:RFG
|
0.000x |
|
Mobilicom Limited American Depositary Shares
NASDAQ:MOB
|
-0.451x |
|
HLV LIMITED
NSE:HLVLTD
|
0.007x |
|
Uniform Industrial Corp
TW:2482
|
0.006x |
|
Dongwon Metal
KO:018500
|
0.143x |
|
3S KOREA Co. Ltd
KQ:060310
|
-0.004x |
Annual Cash Flow Conversion Efficiency for Bioptik Technology (2017–2025)
The table below shows the annual cash flow conversion efficiency of Bioptik Technology from 2017 to 2025. Review cash generation quality of Bioptik Technology to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | NT$974.69 Million ≈ $30.71 Million |
NT$59.99 Million ≈ $1.89 Million |
0.062x | -64.92% |
| 2024-12-31 | NT$905.27 Million ≈ $28.52 Million |
NT$158.82 Million ≈ $5.00 Million |
0.175x | -29.79% |
| 2023-12-31 | NT$824.15 Million ≈ $25.97 Million |
NT$205.95 Million ≈ $6.49 Million |
0.250x | +225.81% |
| 2022-12-31 | NT$717.83 Million ≈ $22.62 Million |
NT$55.06 Million ≈ $1.73 Million |
0.077x | +229.45% |
| 2021-12-31 | NT$694.54 Million ≈ $21.88 Million |
NT$-41.15 Million ≈ $-1.30 Million |
-0.059x | -763.13% |
| 2020-12-31 | NT$735.66 Million ≈ $23.18 Million |
NT$6.57 Million ≈ $207.09K |
0.009x | -83.27% |
| 2019-12-31 | NT$768.38 Million ≈ $24.21 Million |
NT$41.03 Million ≈ $1.29 Million |
0.053x | +3.64% |
| 2018-12-31 | NT$811.73 Million ≈ $25.57 Million |
NT$41.83 Million ≈ $1.32 Million |
0.052x | +314.97% |
| 2017-12-31 | NT$887.42 Million ≈ $27.96 Million |
NT$11.02 Million ≈ $347.16K |
0.012x | -- |
About Bioptik Technology
Bioptik Technology Incorporation engages in the manufacturing, wholesale, and retail of biotechnology and medical equipment in Taiwan and internationally. The company offers blood glucose, cholesterol, uric acid, hemoglobin and acid multi-function monitoring systems under the EasyMate, EasySure, and EasyTouch brand name, as well as PeTouch, a glucose monitoring system for dogs and cats. It also p… Read more